The Nation’s First State-Authorized Medical Marijuana Research Program

The Nation’s First State-Authorized Medical Marijuana Research Program

Dr. Brooke Worster, a physician at Thomas Jefferson University’s Sidney Kimmel Medical College, joins High Society with Paxton Quigley to talk about the nation’s first state-authorized medical marijuana research program underway in Philadelphia where investigators have begun two studies. 

Dr. Worster, lead investigator on a cannabis research staff of 10, tells High Society that the first observational investigation will focus on the impact of cannabis patients’ quality of life among those suffering from any one of Pennsylvania’s 23 qualifying conditions. 

The second study will assemble a smaller focus group to look at MMJ patients’ experiences obtaining patient certification from the state and what they’ve confronted in dispensaries. 

A unique aspect of Dr. Worster’s study: this is the first time in the United States that a cannabis producer has partnered with academic researchers.

Enter Ethos Cannabis, which is collaborating with this important research. 

Ethos’ CEO Teddy Scott, Ph.D. talks about their groundbreaking research agreement. 

For starters, Ethos is funding all of Thomas Jefferson University’s research, which is estimated to cost hundreds of thousands of dollars a year. Ethos Cannabis’ involvement also provides the researchers with high quality cannabis ensuring quality control.

Without a partnership with a cannabis dispensary, Dr. Worster noted, there is no no way to tell what patients are using or have used to address their symptoms. 

 “Working with Ethos, now we can have tighter control. This is light years above anything that we’ve been previously capable of doing,” Worster said.

Kudos to Ethos Cannabis and good luck to Thomas Jefferson University’s medical cannabis researchers.

In the near future, which Quigley will be reporting on, a planned clinical trial at Thomas Jefferson University’s Sidney Kimmel Medical College will look at marijuana’s ability to help cancer patients struggling with nausea and weight loss.